Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients Who Require Concomitant CYP-Metabolized Medications
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events (10/13 vs 14/17; = .73), drug intolerability (1/5 vs 4/11; = 1), or 90-day mortality (0/13 vs 1/17; = 1) in patients receiving clarithromycin vs azithromycin.
References
1.
Shimomura H, Andachi S, Aono T, Kigure A, Yamamoto Y, Miyajima A
. Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes. J Pharm Health Care Sci. 2016; 1:32.
PMC: 4728759.
DOI: 10.1186/s40780-015-0029-0.
View
2.
Griffith D, Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, Gordin F
. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367-416.
DOI: 10.1164/rccm.200604-571ST.
View
3.
Falkinham 3rd J
. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015; 36(1):35-41.
DOI: 10.1016/j.ccm.2014.10.003.
View
4.
Akiyama N, Inui N, Mori K, Nakamura Y, Hayakawa H, Tanaka S
. Effect of rifampicin and clarithromycin on the CYP3A activity in patients with complex. J Thorac Dis. 2019; 11(9):3814-3821.
PMC: 6790468.
DOI: 10.21037/jtd.2019.09.06.
View
5.
Wallace Jr R, Brown B, Griffith D, Girard W, Murphy D
. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996; 153(6 Pt 1):1766-72.
DOI: 10.1164/ajrccm.153.6.8665032.
View